Acquisition

6 Months Ended

Jun. 29, 2025

Discontinued Operations and Disposal Groups [Abstract]

Acquisition

Acquisition

On February 24, 2025, we executed a definitive agreement to acquire substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG (the "VI Business"). The acquisition adds a broad suite of coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters, which will complement our interventional product portfolio. For additional information regarding the acquisition of the VI Business, see Note 15, Subsequent events.

For the three and six months ended June 29, 2025, we incurred acquisition-related costs of $11.2 million and $15.6 million, respectively, which were recognized in selling, general and administrative expenses in the Condensed Consolidated Statement of Income.